Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.3478
+0.0327 (10.38%)
At close: Jun 30, 2025, 4:00 PM
0.3209
-0.0269 (-7.73%)
After-hours: Jun 30, 2025, 7:59 PM EDT

Company Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.

The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection.

In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.

The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.

Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Plus Therapeutics, Inc.
Plus Therapeutics logo
Country United States
Founded 1996
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Marc Hedrick

Contact Details

Address:
2710 Reed Road, Suite 160
Houston, Texas 77051
United States
Phone 737 255 7194
Website plustherapeutics.com

Stock Details

Ticker Symbol PSTV
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001095981
CUSIP Number 72941H400
ISIN Number US72941H5090
Employer ID 33-0827593
SIC Code 3841

Key Executives

Name Position
Dr. Marc H. Hedrick M.B.A., M.D. President, Chief Executive Officer and Director
Dr. Michael Stanley Rosol Ph.D. Chief Development Officer
Desiree Smith Corporate Controller
Russell W. Bradley President and GM of CNSide Diagnostics

Latest SEC Filings

Date Type Title
Jun 25, 2025 SCHEDULE 13G/A Filing
Jun 23, 2025 EFFECT Notice of Effectiveness
Jun 23, 2025 RW Filing
Jun 23, 2025 424B3 Prospectus
Jun 20, 2025 8-K Current Report
Jun 20, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jun 18, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Jun 17, 2025 8-K Current Report
Jun 9, 2025 DRS [Cover] Draft Registration Statement
Jun 6, 2025 8-K Current Report